Pascal Touchon, Atara Biotherapeutics CEO
November 9, 2023 07:13 AM EST
R&D
Cell/Gene Tx

Atara Bio­ther­a­peu­tic­s' stock drops near­ly 50% af­ter PhII tri­al fail in MS

Katherine Lewin

News Reporter

Atara Bio­ther­a­peu­tics’ cell ther­a­py flunked a Phase II study in pro­gres­sive mul­ti­ple scle­ro­sis, miss­ing the pri­ma­ry end­point as well as flu­id and imag­ing bio­mark­ers, …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Pfiz­er look­ing to sell hos­pi­tal drugs unit — re­ports

'Ex­per­tise is a re­al thing': FDA com­mis­sion­er warns of po­lit­i­cal risk to agency

As­traZeneca CEO reaf­firms com­mit­ment to Chi­na fol­low­ing ex­ec­u­tive's de­ten­tion

Mer­ck, As­traZeneca tout Phase 3 win for can­cer-turned-rare dis­ease drug

Sanofi, Ope­nAI, For­ma­tion Bio de­but pa­tient re­cruit­ing tool, will use in Phase 3 mul­ti­ple scle­ro­sis stud­ies

sponsored

What Will It Take to Re­verse Fi­bro­sis in Pa­tients with Ad­vanced MASH?

A service from the Financial Times